Grant✓ Small businesses may apply
Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
National Institutes of Health
- Opportunity #
- PAR-25-346
- Agency
- National Institutes of Health
- ALN (CFDA)
- 93.394, 93.393, 93.121, 93.396, 93.395, 93.399
- Status
- posted
- Posted
- Dec 11, 2024
- Closes
- Jan 7, 2028
- Funding instrument
- Grant
- Category
- Education, Health
- Cost sharing required
- No
Who can apply
- •For profit organizations other than small businesses
- •State governments
- •Private institutions of higher education
- •Public and State controlled institutions of higher education
- •Independent school districts
- •City or township governments
- •Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- •Special district governments
- •Public housing authorities/Indian housing authorities
- •County governments
- •Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- •Others (see text field entitled "Additional Information on Eligibility" for clarification)
- •Small businesses
- •Native American tribal governments (Federally recognized)
- •Native American tribal organizations (other than Federally recognized tribal governments)
Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Synopsis
Through this engineering-oriented Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.
Contact
National Institutes of Health · grantsinfo@nih.gov